< 1 minute read
Sep. 18, 2021

BI 730357: An Oral RORy Nuclear Receptor Antagonist

BI 730357

oral RORy nuclear receptor antagonist on-going Ph. II for psoriasis (QD dosing) 50k cmpd high-conc. frag. screen + scaff. hop ACS Med. Chem. Lett., Jan. 5, 2021 Boehringer Ingelheim, Ridgefield, CT

drughunter.com
Drug Hunter Team
Loading...

twitterlinkedinemail

Other molecules you may be interested in